Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 11.02 3.96% 0.42
RUBY closed up 3.96 percent on Monday, August 19, 2019, on 1.39 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RUBY trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 3.96%
Oversold Stochastic Weakness 3.96%
New 52 Week Closing Low Bearish 10.31%
New 52 Week Low Weakness 10.31%
Multiple of Ten Bearish Other 10.31%
Wide Bands Range Expansion 10.31%
Down 3 Days in a Row Weakness 10.31%

Older signals for RUBY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Therapies For Cancer Autoimmune Disease Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
Is RUBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 26.9
52 Week Low 9.96
Average Volume 211,529
200-Day Moving Average 15.8943
50-Day Moving Average 13.7268
20-Day Moving Average 12.2495
10-Day Moving Average 11.127
Average True Range 0.8481
ADX 27.95
+DI 16.2294
-DI 29.8092
Chandelier Exit (Long, 3 ATRs ) 13.4457
Chandelier Exit (Short, 3 ATRs ) 12.504300000000001
Upper Bollinger Band 15.0631
Lower Bollinger Band 9.4359
Percent B (%b) 0.28
BandWidth 45.938202
MACD Line -1.0306
MACD Signal Line -0.9163
MACD Histogram -0.1143
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.88
Resistance 3 (R3) 11.87 11.59 11.73
Resistance 2 (R2) 11.59 11.37 11.59 11.68
Resistance 1 (R1) 11.30 11.23 11.45 11.31 11.64
Pivot Point 11.02 11.02 11.09 11.02 11.02
Support 1 (S1) 10.73 10.80 10.88 10.74 10.40
Support 2 (S2) 10.45 10.66 10.45 10.36
Support 3 (S3) 10.16 10.45 10.31
Support 4 (S4) 10.17